Today’s article highlights “a trio of biotech companies scheduled to make initial public offerings this week in what appears to be a favorable climate for new issues in the industry.” First up? A biopharmaceutical company focused on developing novel treatment options for patients with rare neurological disorders, and whose main product seeks to treat excessive daytime sleepiness in adults suffering from narcolepsy (a $1.8 billion market in the U.S.). For more on these three biotech IPOs, CLICK HERE.